pharmaphorum

MAY 27, 2021

It is thought that around five million women in the US have uterine fibroids that cause symptoms, with two-thirds of them inadequately treated with current drugs – generally off-label oral contraceptives or injectable gonadotropin releasing hormone (GnRH) agonists like leuprolide acetate or goserelin acetate.

Hormones 98

Hormones Sales Marketing Drugs 98

Pharmaceutical Technology

MAY 25, 2023

Mellozzan contains the sleep hormone melatonin and is indicated for use in children with attention deficit hyperactivity disorder (ADHD) and sleep difficulties. The deal includes licence income for specified individual key markets along with profit sharing on future Mellozzan sales.

Hormones 130

Hormones Engineer Licensing Licensing 130

Pharmaceutical Technology

OCTOBER 13, 2022

The hormone is produced endogenously in the body by the pineal gland. When light is detected by the retina, it causes the pineal gland to inhibit melatonin release, preventing the feelings of sleepiness associated with the hormone. In 1995, the UK government classified it as a medicine making its over-the-counter sale illegal.

Drugs 147

Drugs Hormones Sales Medicine 147

pharmaphorum

SEPTEMBER 15, 2021

If approved, linzagolix will be the only drug in the class with a dosing regimen intended for women with uterine fibroids who cannot or do not want to take hormone therapy, as well as options for those women happy to do so, according to ObsEva.

Hormones 95

Hormones Drugs FDA Approval Sales 95

Pharmaceutical Technology

JUNE 6, 2023

Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV).

Hormones 100

Hormones In-Vitro Genotype Bacteria 100

pharmaphorum

AUGUST 3, 2022

Gilead Sciences’ investment in oncology has started to provide a solid return, with sales of cancer therapies breaching the $500 million threshold for the first time in the second quarter.

Sales 104

Sales Hormones Drugs Antibody 104

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is indicated for the treatment of metastatic hormone sensitive prostate cancer. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Rezvilutamide overview Rezvilutamide is an antineoplastic agent.

Medicine 100

Medicine Hormones Production Clinical Trials 100

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is indicated for the treatment of metastatic hormone sensitive prostate cancer. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Rezvilutamide overview Rezvilutamide is an antineoplastic agent.

Medicine 100

Medicine Hormones Production Clinical Trials 100

pharmaphorum

AUGUST 15, 2022

At this year’s ASCO congress, the Trop2-targeting antibody-drug conjugate (ADC) was found to improve progression-free survival significantly in in patients with hormone receptor-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment.

HR 77

HR Hormones Sales Antibody 77

XTalks

JANUARY 23, 2024

Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.

Development 72

Development Hormones Drugs Trials 72

pharmaphorum

MARCH 10, 2022

Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries to achieve labelling parity with rival drugs from Pfizer/Astellas and Johnson & Jonson, and fulfil its aim of €3 billion in peak sales for the drug.

Hormones 81

Hormones Sales Drugs Marketing 81

pharmaphorum

AUGUST 8, 2022

The US regulator has approved Nubeqa (darolutamide) in combination with docetaxel chemotherapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), adding to its earlier indication in non-metastatic castration-resistant prostate cancer (nmCRPC). billion) blockbuster.

Sales 59

Sales Hormones FDA Approval Marketing 59

pharmaphorum

AUGUST 16, 2022

The study – which included an all-comer population of men with mCRPC – showed that Lynparza plus Johnson & Johnson’s hormonal therapy Zytiga (abiraterone) reduced the risk of disease progression or death by 34% versus Zytiga alone, with radiographic progression-free survival (rPFS) of 24.8 months and 16.6 months, respectively.

Hormones 109

Hormones Gene Sales Trials 109

pharmaphorum

APRIL 25, 2022

The Swiss pharma said in its update that the acelERA trial comparing giredestrant to physician’s choice of endocrine therapy for previously-treated hormone receptor (HR)-positive, HER2-negative breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). Ocrevus rose 18% to CHF 1.4

Trials 69

Trials Hormones HR Sales 69

Pharmaceutical Technology

APRIL 19, 2023

In 2012, Bayer entered a five-year, multi-target collaboration with Evotec which yielded six non-hormonal pre-clinical candidates, two of which advanced to Phase I development: BAY2328065 and BAY2395840.

Gene Therapy 130

Gene Therapy Hormones Production Sales 130

Pharmaceutical Technology

SEPTEMBER 8, 2022

The information contained within the download document is intended for pharmacists, pharmaceutical executives, sales managers, manufacturers, business development managers, pharmaceutical sales representatives, and any other individual involved in the pharmaceutical compounding sector. . • Test method development.

Marketing 130

Marketing Pharmacy Containment Sales 130

pharmaphorum

MARCH 23, 2021

The big Swiss pharma added this drug to its pipeline after it swooped for Endocyte and so far it looks like a good piece of business, with potential blockbuster sales predicted for the drug if it makes it to market. Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1

Trials 124

Trials Hormones Sales Regulation 124

pharmaphorum

OCTOBER 11, 2020

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s rival drug Verzenio.

Trials 52

Trials HR Hormones Drugs 52

pharmaphorum

DECEMBER 3, 2021

When this happens, the first line of drug treatment if the tumours are hormone-sensitive is ADT, with chemotherapy layered on top if needed. Around 95% of prostate cancers are localised at diagnosis and treated with surgery or radiotherapy, but tend to relapse.

Trials 98

Trials Sales Hormones Drugs 98

pharmaphorum

FEBRUARY 21, 2022

It’s a key moment for the two companies, as expansion into HER2-low breast cancer has been held up as a key requirement for Enhertu (trastuzumab deruxtecan) if it is to achieve its multibillion-dollar sales expectations. billion to Daiichi Sankyo if all the ADC’s development and sales objectives are achieved.

Trials 132

Trials Sales Hormones Drugs 132

Pharmaceutical Technology

MARCH 10, 2023

Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity.

Manufacturing 147

Manufacturing Production Containment Antibody 147

XTalks

NOVEMBER 3, 2022

Mounjaro has thus taken off stronger than expected, surpassing Wall Street sales forecasts during the third quarter. Mounjaro was approved this summer as a Type 2 diabetes treatment and is the first diabetes drug with dual action, targeting two hormones involved in insulin production and appetite (GIP and GLP-1).

Sales 98

Sales FDA Approval Production Insulin 98

The Pharma Data

MARCH 20, 2023

We are therefore delighted that patients in China will now have a new treatment option for metastatic hormone-sensitive prostate cancer that delays disease progression, extends survival and maintains quality of life”, said Christine Roth, Member of the Executive Committee of Bayer’s Pharmaceuticals Division and Head of the Oncology SBU at Bayer.

Hormones 40

Hormones Trials Sales Development 40

The Pharma Data

MARCH 23, 2023

The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline.

Hormones 40

Hormones Trials Branding Development 40

pharmaphorum

MARCH 24, 2022

Studies are on the go in the pre-chemotherapy setting in CRPC, as well as in metastatic hormone-sensitive prostate cancer (HSPC) patients who are treatment-naïve or with only short-term use of standard first-line hormonal therapies.

Hormones 59

Hormones Sales FDA Approval Drugs 59

pharmaphorum

AUGUST 11, 2022

Analysts at Jefferies have previously predicted that sales could reach $600 million in the current indication, with additional upside if it gets approved for further uses, which could include the pre-chemotherapy setting in CRPC, as well as in metastatic hormone-sensitive prostate cancer (HSPC) patients who are treatment-naïve or with only short-term (..)

Hormones 64

Hormones Production Sales Marketing 64

pharmaphorum

AUGUST 11, 2020

A phase 3 trial is expected to begin in 2021 and the company says that the compound could generate peak sales of more than a billion euros globally. At the beginning of this year, KaNDy completed a phase 2b trial of its first-in-class drug NT-814, showing activity against symptoms of the menopause such as hot flashes and night sweats.

Drugs 96

Drugs Hormones Marketing Trials 96

The Pharma Data

AUGUST 11, 2020

After this, the agreement promises further “triple digit million” milestone payments to be made once sales goals are hit. It has been projected that, if successful, the drug could rake in as much as €1 billion in global sales at its peak. The deal is expected to close by September this year. Matt Fellows. Source link.

Hormones 52

Hormones Sales Medicine Development 52

pharmaphorum

OCTOBER 14, 2022

The EU decision follows a green light from the FDA for longer-duration use of Mirena – an intrauterine device (IUD) that also delivers the hormone levonorgestrel – in August. Approximately 17% of women of reproductive age (around 160 million worldwide) use intrauterine contraception, including hormone-releasing products.

Hormones 59

Hormones Compliance Clinical Trials Clinical Trials 59

pharmaphorum

MARCH 8, 2021

The cost-effectiveness agency is assessing use of Lynparza (olaparib) in patients with tumours that carry BRCA1 or BRCA2 mutations who have previously been treated with the hormone therapies abiraterone and enzalutamide but have relapsed.

Hormones 98

Hormones Marketing Trials DNA 98

XTalks

MAY 26, 2022

In this episode, Ayesha discussed the FDA approval of Eli Lilly’s diabetes injection Mounjaro (tirzepatide) for the treatment of adults with type 2 diabetes This is a great advancement in the diabetes space as Mounjaro is a first-in-class medicine that targets the activity of two hormones involved in hunger and blood sugar control (GLP-1 and GIP).

Life Science 52

Life Science FDA Approval Hormones Sales 52

The Pharma Data

MAY 14, 2021

It is a laser targeted combination of powerful series of protocols set in a unique order and timing aimed at naturally eliminating all types of acne in as little as 7 days, restoring your intestinal and hormonal balance and thus helping you gain the lasting perfect clear skin you deserve. The website’s content and the product for sale.

Production 52

Production Hormones Sales Licensing 52

pharmaphorum

JANUARY 26, 2023

In Europe, approximately 531,000 breast cancer patients are diagnosed annually, with around 141,000 deaths, and around half of all cases would fall under the HER2-low classification, split between patients with both hormone receptor (HR) positive and HR negative disease. billion upfront and milestones that could drive the total value to $6.9

HR 52

HR Sales Hormones FDA Approval 52

Pharmaceutical Technology

FEBRUARY 14, 2023

The company filed heterocyclic composition patents in areas such as PAD4 inhibitors, factor Xa inhibitors, and nuclear hormone receptor modulators. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects.

Antibody 130

Antibody Hormones DNA Licensing 130

Pharmaceutical Technology

FEBRUARY 18, 2023

Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Hormones 100

Hormones Production Development Clinical Trials 100

The Pharma Data

MAY 13, 2021

Well, sleep keeps the “hunger hormones” (ghrelin and leptin) in check. When you don’t get enough sleep, you create an imbalance between these hormones and that leads to an increased appetite which, in turn, will put your weight loss journey to a halt. Well, sleep keeps the “hunger hormones” (ghrelin and leptin) in check.

Hormones 52

Hormones Production Packaging Packaging 52

pharmaphorum

OCTOBER 24, 2022

for Myovant – which develops hormonal therapies for conditions like uterine fibroids, endometriosis and prostate cancer – but that was deemed inadequate and was turned down earlier this month. Sales of the two products were $4 million and $36 million respectively in Myovant’s fiscal first quarter ended 30 June 2022.

Hormones 73

Hormones Production Marketing Sales 73